TrialCancer immunology, immunotherapy : CII2025

Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter Phase II clinical trial.

Jiamin Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.